Indiana University raises $1.2 million for research at tailgate gala

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE INDIANA UNIVERSITY Melvin and Bren Simon Cancer Center raised nearly $1.2 million for cancer research at its fourth annual Chuckstrong Tailgate Gala.

Hosted by the Indianapolis Colts and head coach Chuck Pagano at the Indiana Farm Bureau Football Center, the gala raised the funds through corporate sponsorships, live and silent auctions, and the annual Chuckstrong Giving Challenge. The total includes $250,000 given by the Jim Irsay family, and $50,000 from the coach and his wife, Tina.

The record-setting amount also included $30,000 raised from 25 people who paid $1,200 each for the chance to catch a touchdown pass from quarterback Andrew Luck. In all, the Chuckstrong initiative has raised $3.7 million for cancer research at IU.

Top-level “touchdown” sponsors for the event were Anthem Blue Cross and Blue Shield, DairyChem, the Efroymson Family Fund, Huntington Bank, Lilly Oncology, Sol and Kay Raso, the Throgmartin family, the IU Simon Cancer Center, the IU School of Medicine, and Indiana Knitwear.

Table of Contents

YOU MAY BE INTERESTED IN

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login